CTIS2023-503950-11-00招募中1 期
Multicenter, randomized, double-blind, Phase III study of intravenous TAD® 600 mg/4 ml solution for injection to evaluate efficacy and safety in preventing myocardial injury in patients with pneumonia - GLT-07-22
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 178
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Patients with an age of = 18 and = 80 years, Diagnosis of CAP or HAP requiring hospitalization, Patients with one of the following (a or b): a. At least one cardiovascular comorbidity: • Hypertension • Permanent atrial fibrillation • History of ischemic heart disease • Heart failure • Diabetes • Cardiac Valvular Disease • Previous (= 6 months) episode of myocarditis or pericarditis • Chronic kidney disease (eGFR = 60 mL/min and = 30 mL/min) b. Very high risk of developing cardiovascular diseases according to the SCORE2 and SCORE2-OP risk models for moderate risk European regions (score = 7.5% for patients < 50 years old, score = 10% for patients 50-69 years old, and score = 15% for patients = 70 years old), Provision of written informed consent as approved by the Ethics Committee (EC)
排除标准
- •Active malignancy, Pregnant or breastfeeding women, Women of child-bearing potential not using at least one effective contraceptive method for the entire trial, Participation in other investigational drug or device clinical trials within 30 days prior to study screening, Patients legally or mentally incapacitated unable to give informed consent for the participation in this trial, Patients unable or unwilling to comply with the appointments after hospitalization or with all the requirements of the Protocol, End-stage renal failure (eGFR < 30 mL/min), Severe liver disease, History of hypersensitivity to glutathione, Use of drugs containing sacubitril, Use of drugs with antioxidant activity in the last 3 months, Use of narcotics, Use of invasive mechanical ventilation, Recent (< 3 months) ACS (STEMI, NSTEMI, UA), myocardial revascularization, myocarditis, acute pericarditis episodes
研究者
相似试验
进行中（未招募）
不适用
Multicenter, randomized, double-blind, phase III study of REVLIMID(Lenalidomide) versus placebo in patients with low risk myelodysplastic syndrome (low and intermediate-1 IPSS) with alteration in 5q- and anemia without the need of transfusion.Patients who are 18 years old or older, who suffer from low risk myelodysplastic syndrome associated to the loss of 5q without transfusion requirementsMedDRA version: 16.1Level: LLTClassification code 10067096Term: 5q minus myelodysplastic syndromeSystem Organ Class: 100000004864EUCTR2009-013619-36-FRFundación General de la Universidad de Salamanca60
进行中（未招募）
1 期
Multicenter, randomized, double-blind, phase III study of REVLIMID(Lenalidomide) versus placebo in patients with low risk myelodysplastic syndrome (low and intermediate-1 IPSS) with alteration in 5q- and anemia without the need of transfusion.Patients who are 18 years old or older, who suffer from low risk myelodysplastic syndrome associated to the loss of 5q without transfusion requirementsMedDRA version: 20.1Level: LLTClassification code 10067096Term: 5q minus myelodysplastic syndromeSystem Organ Class: 100000004864EUCTR2009-013619-36-DEFundación General de la Universidad de Salamanca60
进行中（未招募）
不适用
BIBF 1120 plus pemetrexed compared to placebo plus pemetrexed in 2nd line nonsquamous NSCLCStage IIIB/IV or recurrent non small cell lung cancer. non squamous histologyMedDRA version: 14.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-002072-10-HUBoehringer Ingelheim International GmbH1,300
进行中（未招募）
不适用
Multicenter, randomised, double-blind, Phase III trial to investigate theefficacy and safety of oral BIBF 1120 plus standard pemetrexed therapycompared to placebo plus standard pemetrexed therapy in patients withstage IIIB/IV or recurrent non small cell lung cancer after failure of firstline chemotherapy - BIBF plus Pemetrexed in 2nd line NSCLC patientsStage IIIB/IV or recurrent non small cell lung cancer. non squamous histologyMedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVMedDRA version: 9.1Level: LLTClassification code 10029515Term: Non-small cell lung cancer recurrentEUCTR2008-002072-10-NLBoehringer Ingelheim International GmbH1,300
进行中（未招募）
不适用
Multicenter, randomised, double-blind, Phase III trial to investigate theefficacy and safety of oral BIBF 1120 plus standard pemetrexed therapycompared to placebo plus standard pemetrexed therapy in patients withstage IIIB/IV or recurrent non small cell lung cancer after failure of firstline chemotherapy - BIBF plus Pemetrexed in 2nd line NSCLC patientsStage IIIB/IV or recurrent non small cell lung cancer. non squamous histologyMedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVMedDRA version: 9.1Level: LLTClassification code 10029515Term: Non-small cell lung cancer recurrentEUCTR2008-002072-10-ROBoehringer Ingelheim International GmbH1,300